Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125


Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening.

Coldman AJ, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan DJ, Lee M, Elwood-Martin R, Gentile L, Peacock S, Stuart GCE, Franco EL, Ogilvie GS.

Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524. [Epub ahead of print]


Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2019 May 15;144(10):2587-2595. doi: 10.1002/ijc.31976. Epub 2018 Dec 24.


Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.

Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, Ceballos KM, Jang D, Chernesky M, Franco EL, Ogilvie GS, Coldman AJ, Krajden M.

J Clin Virol. 2018 Nov;108:32-37. doi: 10.1016/j.jcv.2018.09.004. Epub 2018 Sep 10.


Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ.

JAMA. 2018 Jul 3;320(1):43-52. doi: 10.1001/jama.2018.7464. Erratum in: JAMA. 2018 Dec 4;320(21):2273.


The OncoSim model: development and use for better decision-making in Canadian cancer control.

Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, Garner R, Miller AB, Evans WK, Popadiuk CM, Wolfson M, Coldman AJ.

Curr Oncol. 2017 Dec;24(6):401-406. doi: 10.3747/co.24.3850. Epub 2017 Dec 20.


Post-Loop Electrosurgical Excision Procedure High-Risk Human Papillomavirus Testing as a Test of Cure: The British Columbia Experience.

Ceballos KM, Lee M, Cook DA, Smith LW, Gondara L, Krajden M, van Niekerk DJ, Coldman AJ.

J Low Genit Tract Dis. 2017 Oct;21(4):284-288. doi: 10.1097/LGT.0000000000000349.


Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010.

McGahan CE, Linn K, Guno P, Johnson H, Coldman AJ, Spinelli JJ, Caron NR.

Cancer Causes Control. 2017 Oct;28(10):1105-1116. doi: 10.1007/s10552-017-0950-7. Epub 2017 Sep 8.


Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.

Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M.

J Clin Virol. 2017 Feb;87:23-29. doi: 10.1016/j.jcv.2016.12.004. Epub 2016 Dec 11.


Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.

Coldman AJ, Gondara L, Smith LW, van Niekerk D, Ceballos K, Krajden M, Cook D, Quinlan DJ, Lee M, Stuart GC, Peacock S, Martin RE, Gentile L, Franco EL, Ogilvie GS.

Br J Cancer. 2016 Dec 6;115(12):1487-1494. doi: 10.1038/bjc.2016.368. Epub 2016 Nov 17.


HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.

Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, Lee M, Gentile L, Gondara L, Elwood-Martin R, Peacock S, Stuart G, Franco EL, Coldman AJ.

Int J Cancer. 2017 Jan 15;140(2):440-448. doi: 10.1002/ijc.30454. Epub 2016 Oct 20.


Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, Lacombe J, Miller AB.

Curr Oncol. 2016 Feb;23(Suppl 1):S56-63. doi: 10.3747/co.23.2991. Epub 2016 Feb 29.


Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval.

Ogilvie GS, Smith LW, van Niekerk D, Khurshed F, Pedersen HN, Taylor D, Thomson K, Greene SB, Babich SM, Franco EL, Coldman AJ.

BMC Public Health. 2016 Mar 2;16:213. doi: 10.1186/s12889-016-2865-8.


Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.

Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M.

BMC Cancer. 2015 Dec 16;15:968. doi: 10.1186/s12885-015-1959-5.


Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.

Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Martin RE, Franco EL, Ogilvie G.

J Obstet Gynaecol Can. 2015 May;37(5):412-420. doi: 10.1016/S1701-2163(15)30255-3.


Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

Coldman AJ, Phillips N, Brisson J, Flanagan W, Wolfson M, Nadeau C, Fitzgerald N, Miller AB.

Curr Oncol. 2015 Apr;22(2):e41-50. doi: 10.3747/co.22.2013.


Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ.

Int J Cancer. 2015 Oct 15;137(8):1931-7. doi: 10.1002/ijc.29508. Epub 2015 Jun 3.


HAART slows progression to anal cancer in HIV-infected MSM.

Duncan KC, Chan KJ, Chiu CG, Montaner JS, Coldman AJ, Cescon A, Au-Yeung CG, Wiseman SM, Hogg RS, Press NM.

AIDS. 2015 Jan 28;29(3):305-11. doi: 10.1097/QAD.0000000000000537.


Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program.

Smith LW, Khurshed F, van Niekerk DJ, Krajden M, Greene SB, Hobbs S, Coldman AJ, Franco EL, Ogilvie GS.

BMC Public Health. 2014 Oct 10;14:1060. doi: 10.1186/1471-2458-14-1060.


Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.

Pataky R, Ismail Z, Coldman AJ, Elwood M, Gelmon K, Hedden L, Hislop G, Kan L, McCoy B, Olivotto IA, Peacock S.

J Med Screen. 2014 Dec;21(4):180-8. doi: 10.1177/0969141314549758. Epub 2014 Sep 3.


Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

Davidson A, Chia S, Olson R, Nichol A, Speers C, Coldman AJ, Bajdik C, Woods R, Tyldesley S.

CMAJ Open. 2013 Nov 7;1(4):E134-41. doi: 10.9778/cmajo.20130017. eCollection 2013 Oct.


Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S.

Int J Cancer. 2014 Aug 15;135(4):939-47. doi: 10.1002/ijc.28732. Epub 2014 Feb 4.


Breast cancer survival and prognosis by screening history.

Coldman AJ, Phillips N.

Br J Cancer. 2014 Feb 4;110(3):556-9. doi: 10.1038/bjc.2013.732. Epub 2013 Dec 3.


Assessing the breast cancer risk distribution for women undergoing screening in British Columbia.

Weisstock CR, Rajapakshe R, Bitgood C, McAvoy S, Gordon PB, Coldman AJ, Parker BA, Wilson C.

Cancer Prev Res (Phila). 2013 Oct;6(10):1084-92. doi: 10.1158/1940-6207.CAPR-13-0027. Epub 2013 Aug 20.


Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.


Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, Goel V, Rimer BK, Greene SB, Hobbs S, Coldman AJ, Franco EL.

Int J Cancer. 2013 Dec 15;133(12):2934-43. doi: 10.1002/ijc.28324. Epub 2013 Jul 16.


Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada.

Ogilvie GS, Cook DA, Taylor DL, Rank C, Kan L, Yu A, Mei W, van Niekerk DJ, Coldman AJ, Krajden M.

Vaccine. 2013 Feb 4;31(7):1129-33. doi: 10.1016/j.vaccine.2012.09.085. Epub 2012 Dec 25.


Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ.

Br J Cancer. 2012 Dec 4;107(12):1917-24. doi: 10.1038/bjc.2012.489. Epub 2012 Nov 20.


A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ.

BMC Cancer. 2010 Mar 24;10:111. doi: 10.1186/1471-2407-10-111.


Impact of changing from annual to biennial mammographic screening on breast cancer outcomes in women aged 50-79 in British Columbia.

Coldman AJ, Phillips N, Olivotto IA, Gordon P, Warren L, Kan L.

J Med Screen. 2008;15(4):182-7. doi: 10.1258/jms.2008.008064.


Organized breast screening programs in Canada: effect of radiologist reading volumes on outcomes.

Coldman AJ, Major D, Doyle GP, D'yachkova Y, Phillips N, Onysko J, Shumak R, Smith NE, Wadden N.

Radiology. 2006 Mar;238(3):809-15. Epub 2006 Jan 19.


Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA.

J Clin Oncol. 2005 Apr 20;23(12):2716-25.


Comparison of 1- and 2-year screening intervals for women undergoing screening mammography.

Wai ES, D'yachkova Y, Olivotto IA, Tyldesley S, Phillips N, Warren LJ, Coldman AJ.

Br J Cancer. 2005 Mar 14;92(5):961-6.


Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M.

J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.


Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia.

Laskin JJ, Erridge SC, Coldman AJ, D'yachkova Y, Speers C, Westeel V, Hislop TG, Olivotto IA, Murray N.

Lung Cancer. 2004 Jan;43(1):7-16.


Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.

Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D.

Hum Pathol. 2003 Oct;34(10):1001-8.


Waist-to-hip ratio and breast cancer mortality.

Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, Coldman AJ, Potter JD, Gallagher RP, Hislop TG.

Am J Epidemiol. 2003 Nov 15;158(10):963-8.


The effect of heterogeneity on optimal regimens in cancer chemotherapy.

Murray JM, Coldman AJ.

Math Biosci. 2003 Sep;185(1):73-87.


Local and regional therapy for women with breast cancer in British Columbia.

Hislop TG, Coldman AJ, Olivotto IA, D'yachkova Y, Speers C.

Breast J. 2003 May-Jun;9(3):192-9.


Satisfaction and anxiety for women during investigation of an abnormal screening mammogram.

Hislop TG, Harris SR, Jackson J, Thorne SE, Rousseau EJ, Coldman AJ, Vestrup JA, Wright CJ, Olivotto IA.

Breast Cancer Res Treat. 2002 Dec;76(3):245-54.


Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease.

Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Morabia A, Schuman L, Stewart W, Szklo M, Bain C, Schofield F, Siskind V, Band P, Coldman AJ, Gallagher RP, Hislop TG, Yang P, Kolonel LM, Nomura AM, Hu J, Johnson KC, Mao Y, De Sanjosé S, Lee N, Marchbanks P, Ory HW, Peterson HB, Wilson HG, Wingo PA, Ebeling K, Kunde D, Nishan P, Hopper JL, Colditz G, Gajalanski V, Martin N, Pardthaisong T, Silpisornkosol S, Theetranont C, Boosiri B, Chutivongse S, Jimakorn P, Virutamasen P, Wongsrichanalai C, Ewertz M, Adami HO, Bergkvist L, Magnusson C, Persson I, Chang-Claude J, Paul C, Skegg DC, Spears GF, Boyle P, Evstifeeva T, Daling JR, Hutchinson WB, Malone K, Noonan EA, Stanford JL, Thomas DB, Weiss NS, White E, Andrieu N, Brêmond A, Clavel F, Gairard B, Lansac J, Piana L, Renaud R, Izquierdo A, Viladiu P, Cuevas HR, Ontiveros P, Palet A, Salazar SB, Aristizabel N, Cuadros A, Tryggvadottir L, Tulinius H, Bachelot A, Lê MG, Peto J, Franceschi S, Lubin F, Modan B, Ron E, Wax Y, Friedman GD, Hiatt RA, Levi F, Bishop T, Kosmelj K, Primic-Zakelj M, Ravnihar B, Stare J, Beeson WL, Fraser G, Bullbrook RD, Cuzick J, Duffy SW, Fentiman IS, Hayward JL, Wang DY, McMichael AJ, McPherson K, Hanson RL, Leske MC, Mahoney MC, Nasca PC, Varma AO, Weinstein AL, Moller TR, Olsson H, Ranstam J, Goldbohm RA, van den Brandt PA, Apelo RA, Baens J, de la Cruz JR, Javier B, Lacaya LB, Ngelangel CA, La Vecchia C, Negri E, Marubini E, Ferraroni M, Gerber M, Richardson S, Segala C, Gatei D, Kenya P, Kungu A, Mati JG, Brinton LA, Hoover R, Schairer C, Spirtas R, Lee HP, Rookus MA, van Leeuwen FE, Schoenberg JA, McCredie M, Gammon MD, Clarke EA, Jones L, Neil A, Vessey M, Yeates D, Appleby P, Banks E, Beral V, Bull D, Crossley B, Goodill A, Green J, Hermon C, Key T, Langston N, Lewis C, Reeves G, Collins R, Doll R, Peto R, Mabuchi K, Preston D, Hannaford P, Kay C, Rosero-Bixby L, Gao YT, Jin F, Yuan JM, Wei HY, Yun T, Zhiheng C, Berry G, Cooper Booth J, Jelihovsky T, MacLennan R, Shearman R, Wang QS, Baines CJ, Miller AB, Wall C, Lund E, Stalsberg H, Shu XO, Zheng W, Katsouyanni K, Trichopoulou A, Trichopoulos D, Dabancens A, Martinez L, Molina R, Salas O, Alexander FE, Anderson K, Folsom AR, Hulka BS, Bernstein L, Enger S, Haile RW, Paganini-Hill A, Pike MC, Ross RK, Ursin G, Yu MC, Longnecker MP, Newcomb P, Bergkvist L, Kalache A, Farley TM, Holck S, Meirik O; Collaborative Group on Hormonal Factors in Breast Cancer.

Br J Cancer. 2002 Nov 18;87(11):1234-45.


Effects of positive resection margin and tumor distance from anus on rectal cancer treatment outcomes.

Phang PT, MacFarlane JK, Taylor RH, Cheifetz RE, Davis N, Hay JH, McGregor G, Speers C, Sullivan BJ, Pitts J, Coldman AJ.

Am J Surg. 2002 May;183(5):504-8.


Improving the time to diagnosis after an abnormal screening mammogram.

Olivotto IA, Borugian MJ, Kan L, Harris SR, Rousseau EJ, Thorne SE, Vestrup JA, Wright CJ, Coldman AJ, Hislop TG.

Can J Public Health. 2001 Sep-Oct;92(5):366-71.


Optimal control for a stochastic model of cancer chemotherapy.

Coldman AJ, Murray JM.

Math Biosci. 2000 Dec;168(2):187-200.


Breast cancer survival advantage with radiotherapy.

Ragaz J, Spinelli JJ, Coldman AJ.

Lancet. 2000 Oct 7;356(9237):1270; author reply 1271. No abstract available.


Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial.

Gallagher RP, Rivers JK, Lee TK, Bajdik CD, McLean DI, Coldman AJ.

JAMA. 2000 Jun 14;283(22):2955-60.


Standardized abnormal interpretation and cancer detection ratios to assess reading volume and reader performance in a breast screening program.

Kan L, Olivotto IA, Warren Burhenne LJ, Sickles EA, Coldman AJ.

Radiology. 2000 May;215(2):563-7.


Pion conformal radiation of prostate cancer: results of a randomized study.

Pickles T, Goodman GB, Fryer CJ, Bowen J, Coldman AJ, Duncan GG, Graham P, McKenzie M, Morris WJ, Rheaume DE, Syndikus I.

Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):47-55.


Supplemental Content

Loading ...
Support Center